|
Bipolar Disorder
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetics of long-term treatment outcome in bipolar disorder.
|
26297903 |
2016 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A catalog of genetic loci associated with kidney function from analyses of a million individuals.
|
31152163 |
2019 |
|
Lung Diseases, Interstitial
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.
|
23583980 |
2013 |
|
Lung Diseases, Interstitial
|
0.100 |
GeneticVariation
|
group |
GWASDB |
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.
|
23583980 |
2013 |
|
Adolescent idiopathic scoliosis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease.
|
30019117 |
2018 |
|
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 3
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease.
|
30019117 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these data suggest that DEPTOR has a tumor suppressive activity against pancreatic cancer cells, and its loss of expression may contribute to pancreatic tumorigenesis.
|
25544749 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our study demonstrates that DEPTOR is a tumor suppressor in the prostate, and its depletion promotes tumorigenesis via the activation of mTORC1 and mTORC2 signals.
|
31685947 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DEPTOR acts as a tumor suppressor by limiting EGFR-driven lung adenocarcinoma progression.
|
26896556 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Functional experiments demonstrated that DEPTOR silencing inhibited the proliferation and mobility of HCC cells in vitro and suppressed tumor growth and metastasis of HCC cells in vivo.
|
31228948 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Over-expression of DEPTOR specifically occurs in the multiple myeloma (MM) tumor model and DEPTOR knockdown is cytotoxic to MM cells, suggesting it is a potential therapeutic target.
|
28916338 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, we provide a molecular basis for the synergistic combination of Wnt and mTOR inhibitors in treating colorectal cancer with elevated c-Myc.<b>Significance:</b> The mTOR inhibitor DEPTOR acts as a tumor promoter and could be a potential therapeutic target in colorectal cancer.<i></i>.
|
29666061 |
2018 |
|
Multiple Myeloma
|
0.050 |
Biomarker
|
disease |
BEFREE |
A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity.
|
31395691 |
2019 |
|
Multiple Myeloma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Additionally, the potential for DEPTOR to be deregulated in MM by particular miRNAs was investigated.
|
28420429 |
2017 |
|
Multiple Myeloma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Due to their targeting of DEPTOR, these compounds activate mTORC1 and selectively induce MM cell apoptosis and cell cycle arrest.
|
28916338 |
2017 |
|
Multiple Myeloma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Starting from genome-wide gene-expression profiling to seek important NOTCH1 transcriptional targets, we identified DEP-domain containing mTOR-interacting protein (DEPTOR), which was previously shown to be important in multiple myeloma but remains functionally unclear in other hematological malignancies.
|
27593934 |
2017 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
DEP domain-containing mTOR-interacting protein (DEPTOR)/mammalian Target of Rapamycin (mTOR) signaling plays an important role in carcinogenesis.
|
27144580 |
2016 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Collectively, our study demonstrates that DEPTOR is a tumor suppressor in the prostate, and its depletion promotes tumorigenesis via the activation of mTORC1 and mTORC2 signals.
|
31685947 |
2020 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
DEPTOR regulation was also observed to be independent of HPV E6/E7 oncoproteins, but it might be a molecular co-factor contributing to cervical carcinogenesis.
|
26992219 |
2016 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, a series of assays conducted in DEPTOR knockout or ectopic expression in A549 cells confirmed that DEPTOR inhibited proliferation, migration, and invasion as well as the in vivo tumor growth of lung adenocarcinoma.
|
26896556 |
2016 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Mechanistically, DEPTOR depletion not only activated both mTORC1 and mTORC2 signals to promote cell proliferation and survival, but also induced an AKT-dependent epithelial-mesenchymal transition (EMT) and β-catenin nuclear translocation to promote cell migration and invasion.
|
31685947 |
2020 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The DEGs may function in CRC by interacting with other genes in the PPI network of the top 50 nodes, for example, DEP domain‑containing MTOR‑interacting protein (DEPTOR)‑CCND1, AURKA‑breast carcinoma amplified sequence‑1 (BCAS1), CCND1‑BCAS1, CCND1‑neural precursor cell expressed developmentally downregulated 9 (NEDD9) and CCND1‑mitogen‑activated protein kinase kinase 2 (MAP2K2).
|
28000901 |
2017 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Moreover, we provide a molecular basis for the synergistic combination of Wnt and mTOR inhibitors in treating colorectal cancer with elevated c-Myc.<b>Significance:</b> The mTOR inhibitor DEPTOR acts as a tumor promoter and could be a potential therapeutic target in colorectal cancer.<i></i>.
|
29666061 |
2018 |